Takao S I, Kiyotani K, Sakaguchi T, Fujii Y, Seno M, Yoshida T
Department of Bacteriology, Hiroshima University School of Medicine, Minami-ku, Japan.
J Virol. 1997 Jan;71(1):832-8. doi: 10.1128/JVI.71.1.832-838.1997.
Mechanisms of protection of mice from Sendai virus, which is exclusively pneumotropic and causes a typical respiratory disease, by immunization with recombinant vaccinia viruses (RVVs) were investigated. Although the RVV carrying a hemagglutinin-neuraminidase gene of Sendai virus (Vac-HN) propagated in the noses and lungs of mice by either intranasal (i.n.) or intraperitoneal (i.p.) inoculation, no vaccinia virus antigens were detected in the mucosal layer of upper and lower airways of the i.p.-inoculated mice. The mice immunized i.n. with Vac-HN or Vac-F (the RVV carrying a fusion protein gene of Sendai virus) demonstrated the strong resistance to Sendai virus challenge both in the lung and in the nose, whereas the i.p.-immunized mice showed almost no resistance in the nose but showed a partial resistance in the lung. Titration of Sendai virus-specific antibodies in the nasal wash (NW), bronchoalveolar lavage (BAL), and serum collected from the Vac-F-immunized mice showed that the NW from the i.n.-immunized mice contained immunoglobulin A (IgA) antibodies but no IgG and the BAL from the mice contained both IgA and IgG antibodies. On the other hand, neither IgA nor IgG antibodies were detected in the NW from the i.p.-immunized mice and only IgG antibodies were detected in the BAL, although both i.n.- and i.p.-immunized mice exhibited similar levels of serum IgG, IgA, and neutralizing antibodies. The resistance to Sendai virus in the noses of i.n.-immunized mice could be abrogated by the intranasal instillation of anti-mouse IgA but not of anti-IgG antiserum, while the resistance in the lung was not significantly abrogated by such treatments. These results demonstrate that IgA is a major mediator for the immunity against Sendai virus induced by the RVVs and IgG is a supplementary one, especially in the lung, and that the RVV should be intranasally inoculated to induce an efficient mucosal immunity even if it has a pantropic nature.
研究了用重组痘苗病毒(RVV)免疫小鼠,使其免受仙台病毒侵害的机制。仙台病毒具有严格的嗜肺性,可引发典型的呼吸道疾病。尽管携带仙台病毒血凝素 - 神经氨酸酶基因的RVV(Vac - HN)通过鼻内(i.n.)或腹腔内(i.p.)接种在小鼠的鼻腔和肺部繁殖,但在腹腔接种小鼠的上下呼吸道粘膜层中未检测到痘苗病毒抗原。用Vac - HN或Vac - F(携带仙台病毒融合蛋白基因的RVV)进行鼻内免疫的小鼠在肺部和鼻腔对仙台病毒攻击均表现出强大的抵抗力,而腹腔免疫的小鼠在鼻腔几乎没有抵抗力,但在肺部表现出部分抵抗力。对从Vac - F免疫小鼠收集的鼻洗液(NW)、支气管肺泡灌洗液(BAL)和血清中的仙台病毒特异性抗体进行滴定显示,鼻内免疫小鼠的NW中含有免疫球蛋白A(IgA)抗体,但不含IgG,而小鼠的BAL中同时含有IgA和IgG抗体。另一方面,在腹腔免疫小鼠的NW中未检测到IgA和IgG抗体,在BAL中仅检测到IgG抗体,尽管鼻内和腹腔免疫的小鼠血清IgG、IgA和中和抗体水平相似。鼻内免疫小鼠鼻腔对仙台病毒的抵抗力可通过鼻内滴注抗小鼠IgA而不是抗IgG抗血清来消除,而肺部的抵抗力经此类处理后无明显消除。这些结果表明,IgA是RVV诱导的抗仙台病毒免疫的主要介质,IgG是辅助介质,尤其是在肺部,并且即使RVV具有泛嗜性,也应通过鼻内接种来诱导有效的粘膜免疫。